Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Summit Therapeutics Inc (NASDAQ: SMMT) was $19.58 for the day, down -11.32% from the previous closing price of $22.08. In other words, the price has decreased by -$11.32 from its previous closing price. On the day, 5.6 million shares were traded.
Ratios:
Our analysis of SMMT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.63 and its Current Ratio is at 10.63. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on June 11, 2025, initiated with a Underperform rating and assigned the stock a target price of $12.
On March 26, 2025, Citigroup Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $23 to $35.
Stock Price History:
Over the past 52 weeks, SMMT has reached a high of $36.91, while it has fallen to a 52-week low of $6.78. The 50-Day Moving Average of the stock is -16.15%, while the 200-Day Moving Average is calculated to be -5.09%.
Shares Statistics:
A total of 741.61M shares are outstanding, with a floating share count of 110.30M. Insiders hold about 85.05% of the company’s shares, while institutions hold 13.26% stake in the company.
